Celastrol, a Triterpene Extracted from the Chinese “Thunder of God Vine,” Is a Potent Proteasome Inhibitor and Suppresses Human Prostate Cancer Growth in Nude Mice
Interest in the use of traditional medicines for cancer prevention and treatment is increasing. In vitro, in vivo, and clinical studies suggest the potential use of proteasome inhibitors as novel anticancer drugs. Celastrol, an active compound extracted from the root bark of the Chinese medicine “Thunder of God Vine” (Tripterygium wilfordii Hook F.), was used for years as a natural remedy for inflammatory conditions. Although Celastrol has been shown to induce leukemia cell apoptosis, the molecular target involved has not been identified. Furthermore, whether Celastrol has antitumor activity in vivo has never been conclusively shown. Here, we report, for the first time, that Celastrol potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome (IC50 = 2.5 μmol/L) and human prostate cancer cellular 26S proteasome (at 1-5 μmol/L). Inhibition of the proteasome activity by Celastrol in PC-3 (androgen receptor- or AR-negative) or LNCaP (AR-positive) cells results in the accumulation of ubiquitinated proteins and three natural proteasome substrates (IκB-α, Bax, and p27), accompanied by suppression of AR protein expression (in LNCaP cells) and induction of apoptosis. Treatment of PC-3 tumor–bearing nude mice with Celastrol (1-3 mg/kg/d, i.p., 1-31 days) resulted in significant inhibition (65-93%) of the tumor growth. Multiple assays using the animal tumor tissue samples from both early and end time points showed in vivo inhibition of the proteasomal activity and induction of apoptosis after Celastrol treatment. Our results show that Celastrol is a natural proteasome inhibitor that has a great potential for cancer prevention and treatment. (Cancer Res 2006; 66(9): 4758-65)
Топ-30
Журналы
|
2
4
6
8
10
12
14
16
|
|
|
PLoS ONE
16 публикаций, 3.33%
|
|
|
Oncotarget
11 публикаций, 2.29%
|
|
|
Journal of Biological Chemistry
11 публикаций, 2.29%
|
|
|
Frontiers in Pharmacology
10 публикаций, 2.08%
|
|
|
Molecules
9 публикаций, 1.87%
|
|
|
Cell Death and Disease
7 публикаций, 1.46%
|
|
|
European Journal of Medicinal Chemistry
7 публикаций, 1.46%
|
|
|
Cancer Letters
7 публикаций, 1.46%
|
|
|
Biochemical and Biophysical Research Communications
7 публикаций, 1.46%
|
|
|
European Journal of Pharmacology
7 публикаций, 1.46%
|
|
|
Phytotherapy Research
7 публикаций, 1.46%
|
|
|
International Journal of Molecular Sciences
6 публикаций, 1.25%
|
|
|
Journal of Cellular Physiology
6 публикаций, 1.25%
|
|
|
bioRxiv
6 публикаций, 1.25%
|
|
|
Scientific Reports
5 публикаций, 1.04%
|
|
|
Phytomedicine
5 публикаций, 1.04%
|
|
|
Journal of Ethnopharmacology
5 публикаций, 1.04%
|
|
|
Bioorganic and Medicinal Chemistry Letters
5 публикаций, 1.04%
|
|
|
ACS Chemical Biology
5 публикаций, 1.04%
|
|
|
Molecular Cancer
4 публикации, 0.83%
|
|
|
Cancer Research
4 публикации, 0.83%
|
|
|
Anti-Cancer Drugs
3 публикации, 0.62%
|
|
|
Oncogene
3 публикации, 0.62%
|
|
|
BMC Cancer
3 публикации, 0.62%
|
|
|
Chemical Engineering Journal
3 публикации, 0.62%
|
|
|
International Journal of Pharmaceutics
3 публикации, 0.62%
|
|
|
Bioorganic and Medicinal Chemistry
3 публикации, 0.62%
|
|
|
Pharmacology and Therapeutics
3 публикации, 0.62%
|
|
|
International Journal of Cancer
3 публикации, 0.62%
|
|
|
2
4
6
8
10
12
14
16
|
Издатели
|
20
40
60
80
100
120
140
|
|
|
Elsevier
135 публикаций, 28.07%
|
|
|
Springer Nature
72 публикации, 14.97%
|
|
|
Wiley
41 публикация, 8.52%
|
|
|
MDPI
27 публикаций, 5.61%
|
|
|
Taylor & Francis
22 публикации, 4.57%
|
|
|
Frontiers Media S.A.
18 публикаций, 3.74%
|
|
|
American Chemical Society (ACS)
18 публикаций, 3.74%
|
|
|
Public Library of Science (PLoS)
17 публикаций, 3.53%
|
|
|
Royal Society of Chemistry (RSC)
16 публикаций, 3.33%
|
|
|
Impact Journals
13 публикаций, 2.7%
|
|
|
American Society for Biochemistry and Molecular Biology
10 публикаций, 2.08%
|
|
|
Spandidos Publications
9 публикаций, 1.87%
|
|
|
American Association for Cancer Research (AACR)
9 публикаций, 1.87%
|
|
|
openRxiv
6 публикаций, 1.25%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
5 публикаций, 1.04%
|
|
|
Oxford University Press
5 публикаций, 1.04%
|
|
|
Bentham Science Publishers Ltd.
4 публикации, 0.83%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
3 публикации, 0.62%
|
|
|
SAGE
3 публикации, 0.62%
|
|
|
Georg Thieme Verlag KG
3 публикации, 0.62%
|
|
|
S. Karger AG
2 публикации, 0.42%
|
|
|
Mary Ann Liebert
2 публикации, 0.42%
|
|
|
American Society for Microbiology
2 публикации, 0.42%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 публикации, 0.42%
|
|
|
American Society of Hematology
2 публикации, 0.42%
|
|
|
Cold Spring Harbor Laboratory
2 публикации, 0.42%
|
|
|
AME Publishing Company
2 публикации, 0.42%
|
|
|
American Society for Cell Biology (ASCB)
2 публикации, 0.42%
|
|
|
IGI Global
2 публикации, 0.42%
|
|
|
20
40
60
80
100
120
140
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.